KEY POINTS
- Drug manufacturers have introduced GLP-1 and GIP-based medications to combat Pakistan’s escalating diabetes and obesity crisis.
- The new domestically produced injections are priced significantly lower than imported versions, dropping costs from hundreds of thousands to under 15,000 rupees.
- Health experts emphasize that while these advanced treatments help regulate blood sugar and hunger, they must be paired with lifestyle changes and used only under medical supervision.
Pharmaceutical companies in Pakistan have taken a decisive step toward addressing a national health emergency by launching advanced medications for diabetes and obesity management. These new treatments, which include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, are designed to help the millions of Pakistanis struggling with high blood sugar. Currently, Pakistan ranks as the third most affected country globally for diabetes, with nearly one in three adults living with the condition.
The most significant impact of this local launch is the dramatic reduction in treatment costs for patients. Previously, these highly effective medications were largely imported, with prices per packet ranging from 150,000 to 300,000 rupees. By manufacturing and supplying these drugs locally, pharmaceutical firms have brought the price down to a range of 5,000 to 15,000 rupees for a four-dose supply. This shift makes life-saving medication accessible to a much broader segment of the population that was previously priced out of modern care.
These advanced injections, which are typically administered once a week, work by improving the body’s insulin response and slowing down the digestive process. This dual action helps patients feel full for longer periods, effectively reducing hunger and helping to manage obesity—a primary driver of type 2 diabetes. Industry leaders noted that all locally introduced medications meet the strict criteria set by the Drug Regulatory Authority of Pakistan (DRAP), ensuring they align with global standards for safety and efficacy.
Despite the excitement surrounding these “miracle” drugs, medical professionals are issuing a strong word of caution. Doctors emphasize that these medications are not a substitute for a healthy lifestyle. Experts pointed to successful examples of diabetes management through disciplined diet and exercise, such as the routine maintained by cricket legend Wasim Akram. The medical community stresses that these drugs should only be used as a supplementary tool under the direct advice and monitoring of a qualified healthcare provider.
The introduction of these drugs comes at a time when Pakistan’s healthcare system is under immense pressure from the rising tide of chronic illnesses. Public health advocates suggest that a holistic approach is necessary, starting with better education in schools about nutrition and the dangers of processed foods. While the availability of cheaper, advanced medication is a massive win for patient care, the ultimate goal remains the prevention of diabetes through systemic changes in physical activity and dietary habits across the country.
